MRA Countdown: 10, 6, 4, 2, ...
Recommendation
27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Mutual Recognition Agreement (MRA) with the US is on track. In a press announcement from 11 June the EMA informed that Luxembourg and the Netherlands have joined the agreement for good manufacturing practice (GMP) inspections between the US Food and Drug Administration (FDA) and EU Member States.
Now 26 countries are included. Germany and Slovakia are the only EU member states that have not been added yet. By 15 July 2019, however, all authorities and countries should have been approved and acknowledged by FDA.
If the agreement is in force (and only then!), the additional full testing of a drug imported from the USA will no longer be necessary. This also applies to countries that have already been recognised.
Source: EMA press release entitled "Two additional countries to benefit from EU-US mutual recognition agreement for inspections".
Related GMP News
28.04.2026FDA remains active in Europe - further Inspections despite MRAs
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight